---
title: Retinal imaging detects early Parkinson
nct_id: NCT07244640
status: RECRUITING
sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07244640"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07244640"
last_fetched: "2026-05-10T14:06:05.445Z"
source: "Parkinson's Pathways (curated)"
---
# Retinal imaging detects early Parkinson

**Goal (in five words):** Retinal imaging detects early Parkinson

**Official Title:** Clinical Study on Non-Invasive Fundus Retinal Detection Technology for Early Diagnosis of Parkinson's Disease

**Trial ID:** [NCT07244640](https://clinicaltrials.gov/study/NCT07244640)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Target Enrollment:** 200 participants
- **Start Date:** 2025-11
- **Completion Date:** 2028-12
- **Conditions:** Parkinson's Disease (PD)
- **Interventions:** non-invasive fundus retinal detection
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

They want to find eye-based signs that could help detect Parkinson's disease earlier by comparing retinal images from people with early PD, atypical parkinsonism, essential tremor, and healthy volunteers. The approach uses non-invasive fundus retinal imaging to take detailed photos of the back of the eye, looking for changes in retinal nerve layers or blood vessel patterns that might correlate with Parkinson's, so no injections or surgery are involved. The study is enrolling people aged 40 to 80, including Parkinson's patients diagnosed within five years at Hoehn and Yahr stage 1 to 2.5, people with atypical or secondary parkinsonism within five years, people with essential tremor, and healthy controls. People with severe eye disease, major heart/liver/kidney problems, active infections or systemic inflammatory diseases, pregnancy, inability to tolerate the imaging, or significant psychiatric disorders are excluded.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* 1\. Aged 40-80 years; 2. Parkinson's Disease Group: Patients who meet the 2015 International Movement Disorder Society clinical diagnostic criteria for Parkinson's disease, with a Hoehn and Yahr stage of 1 to 2.5 and a disease duration of ≤5 years; 3. Parkinson's Syndromes Group: Patients who meet the International Movement Disorder Society diagnostic criteria for atypical parkinson's syndromes (including progressive supranuclear palsy, dementia with Lewy bodies, and corticobasal degeneration), multiple system atrophy (P subtype), or secondary parkinson's syndrome (drug-induced: having taken antipsychotic medications for ≥3 months; vascular: confirmed by brain MRI showing leukoaraiosis/lacunar infarction), with a disease duration of ≤5 years; 4. Essential Tremor Group: Patients who meet the 2018 International Movement Disorder Society clinical diagnostic criteria for essential tremor, with no parkinsonian symptoms, and a disease duration of ≥1 year; 5. Healthy Control Group: Individuals with no parkinsonian symptoms (confirmed by neurological examination) and no use of antipsychotic/dopaminergic medications in the past 3 months; 6. All subjects have provided written informed consent and are willing to comply with the study procedures.

Exclusion Criteria:

* 1\. Presence of severe ocular fundus diseases, such as glaucoma, cataract, retinal detachment, macular degeneration, etc; 2. Inability to tolerate the non-invasive fundus retinal detection; 3. Known allergy or investigator-suspected high risk of allergy to anti-PD drugs; 4. Presence of severe cardiovascular or cerebrovascular diseases (e.g., coronary heart disease, myocardial infarction, stroke, etc.), hepatic or renal dysfunction, cancer, or other conditions that may affect the prognosis; 5. Pregnancy or lactation; 6. Presence of active infectious diseases (e.g., tuberculosis, AIDS) or systemic inflammatory diseases (e.g., rheumatoid arthritis); 7. Presence of psychiatric disorders.
```

## Locations (1)

- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China _(30.2936, 120.1614)_
  - Feng Gao, MD, PhD — (CONTACT) — 13588451471 — 2202012@zju.edu.cn

## Central Contacts

- Feng Gao, MD, PhD — (CONTACT) — 13588451471 — 2202012@zju.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT07244640*  
*HTML version: https://parkinsonspathways.com/trial/NCT07244640*  
*Source data: https://clinicaltrials.gov/study/NCT07244640*